- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05028556
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of Y101D, a Recombinant Anti-PD-L1 and TGF-β Bispecific Antibody for Injection, in Patients With Metastatic or Locally Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will consist of two parts: dose escalation part and cohort expansion part.
In dose escalation part, up to 5 dose-escalation cohorts will be sequentially enrolled in this study. The five dose levels are 1, 3, 10, 20 and 30 mg/kg. DLTs will be evaluated during the first treatment cycle, which is 28 days. The study consists of a 4-week screening period, a 4-week core treatment period for DLT evaluation, a treatment extension period, a safety follow-up visit for approximately 30 days following the last dose of Y101D, and survival follow-ups every 3 months thereafter.
In cohort expansion part, To further characterize safety and efficacy of Y101D, cohort expansion will be allowed in the following two circumstances: MTD cohort expansion if the MTD could be identified; Benefited dose cohort if it could be determined by Investigator.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Cancer Prevention Center, Sun Yat-sen University
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Zhejiang Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18~75 (including 18 and 75 years old), gender is not limited;
- Pathologically confirmed metastatic or locally advanced solid tumors with failure or absence of standard care;
- ECOG physical status score must be 0~1;
- Expected survival of subjects evaluated by the investigator ≥3 months;
- Hemogram: absolute neutrophil count (ANC) ≥1.5×109/L, hemoglobin ≥90g/L (no red blood cells were injected within 14 days before the first administration), platelet ≥90×109/L;
- Liver: bilirubin ≤1.5 times the upper limit of normal value, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal value;If the subject has liver metastasis, ALT and AST are allowed to be less than 5 times the upper limit of normal value;
- Kidney: Serum creatinine ≤1.5 times the upper limit of normal value or creatinine clearance ≥ 60 mL/min (using standard Cockcroft-Gault formula);
- Understand and voluntarily sign written informed consent.
Exclusion Criteria:
- Have received chemotherapy, radiotherapy (local palliative radiotherapy for 14 days) and immunotherapy within 28 days before the first administration, and have received small molecule targeted drugs or Chinese patent drugs with anti-tumor indications within 14 days;
- Major surgery (except diagnostic biopsy) within 28 days prior to the first dose;
- Subjects with central nervous system (CNS) metastases causing clinical symptoms or requiring therapeutic intervention;Patients who had previously received BMs were included if they were asymptomatic ≥4 weeks prior to initial dosing, had stable disease on radiographic findings, and did not require corticosteroid or anticonvulsant therapy;
- Receive any organ transplantation, including allogeneic stem cell transplantation, except those that do not require immunosuppression (e.g. cornea transplantation, hair transplantation);
- Adverse events caused by previous antitumor therapy have not recovered (i.e., grade 1 or at baseline), except for hair loss and grade 2 neuropathy, hormone replacement hypothyroidism, or other confirmed chronic adverse events;
- Subjects with a history of malignancy (non-study tumor) within 3 years prior to the first study administration date (other than skin squamous cell carcinoma and basal cell carcinoma, carcinoma in situ of the cervix or breast, or other non-invasive lesions that the Investigator and Sponsor agree have been cured and have a very low risk of recurrence within 3 years);
- Have a known allergy, hypersensitivity or intolerance to corticosteroids, monoclonal antibodies or human proteins or their excipients;
- Uncontrolled active infection (CTCAE≥2);
- Subjects with severe respiratory diseases judged by the researcher to be unsuitable for inclusion;
- Subjects with a history of serious cardiovascular disease, including previous coronary artery bypass grafting or stent implantation, myocardial infarction or cerebrovascular accident within 6 months, history of congestive heart failure or unstable angina pectoris, uncontrolled severe hypertension, and arrhythmias requiring medication;
- Active autoimmune diseases (such as inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus (sle), hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis, etc.), into the group when the disease is in stable except ZhuangTaiZhe (no need to systemic immune inhibitors to treat symptoms stable under the condition of more than 6 months).
- Subjects with uncontrolled metabolic diseases such as diabetes, severe gastrointestinal bleeding, and severe diarrhea (CTCAE≥2), and subjects with severe gastrointestinal obstruction requiring intervention;
- Human immunodeficiency virus (HIV) antibody positive, hepatitis B virus (HBV) surface antigen positive and HBV DNA test indicated active hepatitis B (HBV-DNA≥1000cps/ml), active hepatitis C (hepatitis C antibody positive and HCV-RNA higher than the detection limit of the analysis method), active syphilis;
- Those who received live (attenuated) virus vaccine within 4 weeks before the first administration;
- Pregnant or lactating women or men or women who have a birth plan within 12 months;
- Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia;
- Subjects with poor compliance or who are considered by the Investigator to be unsuitable for participation in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Y101D
Y101D in subjects with Metastatic or Locally Advanced Solid Tumors
|
Y101D, 1mg/kg, Q2W, intravenous infusion
Y101D, 3mg/kg, Q2W, intravenous infusion
Y101D, 10mg/kg, Q2W, intravenous infusion
Y101D, 20mg/kg, Q2W, intravenous infusion
Y101D, 30mg/kg, Q2W, intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Limiting Toxicities (DLTs)
Time Frame: From the time of the first dose (Day 1) until the 2nd dosing (Day 28)
|
DLTs were assessed using the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0.
|
From the time of the first dose (Day 1) until the 2nd dosing (Day 28)
|
Adverse Events according to CTCAE V5.0
Time Frame: Time Frame: From the start of administration to the end of the study or 28 days after the administration is stopped (up to 6 months and 28 days)
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Time Frame: From the start of administration to the end of the study or 28 days after the administration is stopped (up to 6 months and 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: 12 months (anticipated)
|
OS was defined as the number of days from administration of the first infusion (Day 1) to date of death.
|
12 months (anticipated)
|
Area under the curve (AUC) of Y101D
Time Frame: Up to 1 weeks after the 2nd dosing
|
Up to 1 weeks after the 2nd dosing
|
|
Peak Plasma Concentration (Cmax) of Y101D
Time Frame: Up to 1 weeks after the 2nd dosing
|
Up to 1 weeks after the 2nd dosing
|
|
Half-time (t1/2) of Y101D
Time Frame: Up to 1 weeks after the 2nd dosing
|
Up to 1 weeks after the 2nd dosing
|
|
immunogenicity
Time Frame: From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months).
|
The presence of antibodies directed against the biotherapeutic medicine upon administration, including the ADA and Nab.
|
From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 6 months).
|
Time to Progression (TTP)
Time Frame: 6 months (anticipated)
|
TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression.
|
6 months (anticipated)
|
Objective Response Rate (ORR)
Time Frame: 6 months (anticipated)
|
ORR is defined as percentage of participants who achieved complete response (CR), partial response (PR), based on RESIST 1.1.
|
6 months (anticipated)
|
Duration of Response
Time Frame: 6 months (anticipated)
|
Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in RESIST 1.1.
|
6 months (anticipated)
|
Progression-Free Survival (PFS)
Time Frame: 6 months (anticipated)
|
PFS was defined as the time between the date of first dose of Y101 and either disease progression or death, whichever occurs first.
|
6 months (anticipated)
|
Time to first Response
Time Frame: 6 months (anticipated)
|
Time to first response was defined as the time from the date of first dose of Y101 to the date of initial documentation of a response (PR or better).
|
6 months (anticipated)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Li Zhang, MD, Cancer Prevention Center, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Y101D01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic or Locally Advanced Solid Tumors
-
University Medical Center GroningenActive, not recruiting
-
Merck KGaA, Darmstadt, GermanyCompletedLocally Advanced or Metastatic Solid TumorsHungary
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingLocally Advanced or Metastatic Solid TumorsChina
-
Avistone Biotechnology Co., Ltd.Zhejiang Cancer Hospital; Henan Cancer Hospital; Hunan Cancer Hospital; Peking... and other collaboratorsRecruitingLocally Advanced or Metastatic Solid TumorsChina
-
TYK Medicines, IncRecruitingLocally Advanced or Metastatic Solid TumorsChina
-
Bio-Thera SolutionsRecruitingLocally Advanced or Metastatic Solid TumorsChina
-
Chugai PharmaceuticalRecruitingLocally Advanced or Metastatic Solid TumorsUnited States, Japan
-
Chugai PharmaceuticalRecruitingLocally Advanced or Metastatic Solid TumorsUnited States, Japan
-
Pierre Fabre MedicamentTerminatedLocally Advanced or Metastatic Solid TumorsFrance, Spain
-
OncoMed Pharmaceuticals, Inc.Celgene CorporationCompletedLocally Advanced or Metastatic Solid TumorsUnited States, United Kingdom
Clinical Trials on Cohort 1 of Y101D
-
Janssen Research & Development, LLCCompletedRelapsed or Refractory Hodgkin LymphomaFrance, Germany
-
AstraZenecaActive, not recruitingCOVID-19, SARS-CoV-2Japan
-
XOMA (US) LLCCompletedCongenital HyperinsulinismUnited Kingdom, United States
-
Janssen Research & Development, LLCPharmacyclics LLC.CompletedCD20-positive B-cell Non-Hodgkin LymphomaUnited States, France
-
PfizerCompleted
-
Akesobio Australia Pty LtdCompletedAtopic DermatitisNew Zealand, Australia
-
Anthos Therapeutics, Inc.CovanceCompletedAtrial FibrillationUnited States
-
Wuhan YZY Biopharma Co., Ltd.Unknown
-
MedImmune LLCCompletedHealthyUnited States, Australia, Spain, Germany, Canada, Finland, South Africa, Brazil, Israel